Observational studyCancer medicine2026

Elevation of Eosinophil Proportion After Pembrolizumab Increases the Risk of Immune-Related Adverse Events in Patients With Bladder Cancer.

Kunihiro Odagiri et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.